<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02291419</url>
  </required_header>
  <id_info>
    <org_study_id>CCAZ-2014</org_study_id>
    <nct_id>NCT02291419</nct_id>
  </id_info>
  <brief_title>Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery</brief_title>
  <acronym>INTREPID</acronym>
  <official_title>An Open Label, Randomized Study to Determine the Rate of Cardiovascular Events at 1 yr for Patients With Elevated Troponins Post Major Non-cardiac Surgery and the Impact of Ticagrelor vs Aspirin on the Occurrence of Cardiovascular Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to establish the rate of cardiovascular events in patients
      with elevated troponins levels after major, non-cardiac surgery and to evaluate the efficacy
      and safety of FDA approved study drug (ticagrelor) compared to aspirin in these patients.

      Data from current studies suggest that myocardial injury detected by minor elevations in
      troponin levels within 3 days after non-cardiac surgery may occur in 10-24% of patients and
      is associated with an increased risk of mortality at 30 days and 1 year. There are no current
      guidelines for care of patients with elevated troponin levels in the absence of acute
      coronary syndrome. This study will assess if the increased risk of these patients is
      modifiable by an anti-platelet medication and evaluate the safety of this medication.

      Patients will be randomized in an open label fashion to receive ticagrelor (anti-platelet
      medication) or 81 mg. aspirin. Patients will be followed on study treatment for 12 months,
      with the last contact at one month post treatment discontinuation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this pilot study is to establish the rate of cardiovascular events in
      patients with elevated troponins levels post major, non-cardiac surgery and to evaluate the
      efficacy and safety of ticagrelor treatment compared to aspirin in these patients.

      Data from current studies suggest that myocardial injury detected by minor elevations in
      troponin levels within 3 days after non-cardiac surgery may occur in 10-24% of patients and
      is associated with an increased risk of mortality at 30 days and 1 year. There are no current
      guidelines for care of patients with elevated troponin levels in the absence of acute
      coronary syndrome (ACS) and it is not certain if this is a modifiable disease process.
      Ticagrelor is a direct, reversible inhibitor of the platelet P2Y12ADP-receptor. It has been
      shown to be superior to clopidogrel in the setting of ACS. The clinical benefit of treating
      patients with port-operative troponin elevation with antiplatelet agents remains unexplored.
      The short half-life of ticagrelor makes it favorable to use in this setting.

      This is an open label, randomized, parallel group study comparing ticagrelor to aspirin in
      patients who experience troponin elevations post major non-cardiac surgery. Patients will be
      randomized in an open-label fashion to receive either ticagrelor 90 mg twice daily or aspirin
      81 mg once daily. Patients will be followed for 13 months post randomization (12 months of
      treatment and a phone call 30 days after study drug discontinuation). The maximum duration of
      treatment will be 12 months.

      Follow-up visits will occur at Month 1, Month 6, and Month 12. Phone calls will be made at
      Month 3, Month 9, and at 30 days after study drug discontinuation.

      Up to 1000 patients with post-operative troponin elevation ≥2x ULN within first 7
      postoperative days, will be enrolled in the study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment expectations were not met
  </why_stopped>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiovascular Events</measure>
    <time_frame>up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.</time_frame>
    <description>Time to first occurence of the composite of Cardiovascular Death, Non-fatal Myocardial Infarction, Coronary Revascularization or Non-fatal Stroke. The number of patients with events is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Death</measure>
    <time_frame>Up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.</time_frame>
    <description>Time to first occurence of Cardiovascular death. The number of patients with events was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal Myocardial Infarction or Coronary Revascularization</measure>
    <time_frame>up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.</time_frame>
    <description>Time to first occurence of Non-fatal myocardial infarction or coronary revascularization. The number of participants with events was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Death</measure>
    <time_frame>up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.</time_frame>
    <description>Time to first occurence of All-cause death. The number of participants with events was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal Stroke</measure>
    <time_frame>up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.</time_frame>
    <description>Time to first occurence of Non-fatal stroke. The number of participants with events was reported.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The Number of Participants With Bleeding According to Bleeding Academic Research Consortium (BARC) Definitions</measure>
    <time_frame>up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Myocardial Injury</condition>
  <arm_group>
    <arm_group_label>ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ticagrelor 90mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the aspirin arm will receive aspirin 81 mg daily orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor</intervention_name>
    <description>ticagrelor 90 mg bid</description>
    <arm_group_label>ticagrelor</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>aspirin 81 mg daily</description>
    <arm_group_label>aspirin</arm_group_label>
    <other_name>Bayer, ASA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent before any study related procedures are performed.

          2. A qualifying post-operative T or I troponin elevation (≥2x ULN of assay within 7 days
             of index surgery and during the index hospitalization).

          3. Men and women ≥40 years of age if troponin elevation was identified as part of routine
             post-operative clinical care OR

          4. Men and women ≥55 years of age if troponin elevation was identified post-operatively
             as part of screening for the study.

          5. Undergone non-cardiac surgery requiring an overnight hospital stay.

          6. Women of childbearing potential who are sexually active must have a negative pregnancy
             test at enrollment and agree to use adequate contraception from screening until 30
             days after receiving the last dose of study drug.

          7. Able to be randomized within 35 days following the index surgery.

        Exclusion Criteria:

          1. Post-operative ST-elevation Myocardial Infarction (STEMI).

          2. Post-operative high-risk non-STEMI, defined as patients with elevated troponin with
             either:

               1. active Ischemic EKG changes (≥2 mm of ST-segment depression in at least 2
                  adjacent leads)

               2. ongoing hemodynamic instability thought to be ischemia mediated or

               3. persistent anginal symptoms.

          3. Planned or urgent coronary angiography/revascularization.

          4. A current or ongoing indication for dual antiplatelet therapy (DAPT) as determined by
             the patient's physician.

          5. History of intracranial hemorrhage

          6. Bleeding disorder or active bleeding that prevents ticagrelor or aspirin
             administration.

          7. Taking any of the following medications at the time of randomization: vitamin K
             antagonists, dabigatran, rivaroxaban, apixaban, edoxaban , fondaparinux, cilostazol,
             vorapaxar or LMWHs.

          8. Renal dialysis.

          9. Hepatic impairment with transaminase ≥3x ULN at time of randomization.

         10. Known contra-indication for use of ticagrelor.

         11. Estimated life expectancy of &lt;1 year.

         12. Enrolled in another ongoing drug or device research protocol

         13. A definite non-ischemic explanation for troponin elevation, such as myocarditis or
             pulmonary embolism.

         14. A documented hypersensitivity to aspirin.

         15. Hypersensitivity to ticagrelor or any component of the product.

         16. Neurological or ophthalmic surgery during the index hospitalization.

         17. Patients taking strong CYP3A inhibitors and/or CYP3A inducers that cannot be stopped
             for the course of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Venu Menon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama Health System</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Site Management Service, LLC</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Orthopaedic Institute and Fracture Care Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Georgia Heart Center</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Medical Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLaren Bay Region</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLaren Macomb</name>
      <address>
        <city>Mount Clemens</city>
        <state>Michigan</state>
        <zip>48043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati VA Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center - Cleveland Louis Stokes</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Valley Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA North Texas Health Care System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overlake Hospital Medical Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.</citation>
    <PMID>19717846</PMID>
  </reference>
  <reference>
    <citation>Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators, Devereaux PJ, Chan MT, Alonso-Coello P, Walsh M, Berwanger O, Villar JC, Wang CY, Garutti RI, Jacka MJ, Sigamani A, Srinathan S, Biccard BM, Chow CK, Abraham V, Tiboni M, Pettit S, Szczeklik W, Lurati Buse G, Botto F, Guyatt G, Heels-Ansdell D, Sessler DI, Thorlund K, Garg AX, Mrkobrada M, Thomas S, Rodseth RN, Pearse RM, Thabane L, McQueen MJ, VanHelder T, Bhandari M, Bosch J, Kurz A, Polanczyk C, Malaga G, Nagele P, Le Manach Y, Leuwer M, Yusuf S. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2012 Jun 6;307(21):2295-304. doi: 10.1001/jama.2012.5502. Erratum in: JAMA. 2012 Jun 27;307(24):2590.</citation>
    <PMID>22706835</PMID>
  </reference>
  <reference>
    <citation>POISE Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Málaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008 May 31;371(9627):1839-47. doi: 10.1016/S0140-6736(08)60601-7. Epub 2008 May 12.</citation>
    <PMID>18479744</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <results_first_submitted>February 8, 2017</results_first_submitted>
  <results_first_submitted_qc>February 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2017</results_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Venu Menon</investigator_full_name>
    <investigator_title>MD, FACC, FAHA, Director CICU, CEC-C5, Fellowship Program Cardiovascular Imaging</investigator_title>
  </responsible_party>
  <keyword>ticagrelor</keyword>
  <keyword>non-cardiac surgery</keyword>
  <keyword>elevated troponin</keyword>
  <keyword>myocardial injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ticagrelor</title>
          <description>ticagrelor 90mg bid
ticagrelor: ticagrelor 90 mg bid</description>
        </group>
        <group group_id="P2">
          <title>Aspirin</title>
          <description>Patients in the aspirin arm will receive aspirin 81 mg daily orally
aspirin: aspirin 81 mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Early study termination</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ticagrelor</title>
          <description>ticagrelor 90mg bid
ticagrelor: ticagrelor 90 mg bid</description>
        </group>
        <group group_id="B2">
          <title>Aspirin</title>
          <description>Patients in the aspirin arm will receive aspirin 81 mg daily orally
aspirin: aspirin 81 mg daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&gt; or = to 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Cardiovascular Events</title>
        <description>Time to first occurence of the composite of Cardiovascular Death, Non-fatal Myocardial Infarction, Coronary Revascularization or Non-fatal Stroke. The number of patients with events is reported.</description>
        <time_frame>up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>ticagrelor 90mg bid
ticagrelor: ticagrelor 90 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Patients in the aspirin arm will receive aspirin 81 mg daily orally
aspirin: aspirin 81 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiovascular Events</title>
          <description>Time to first occurence of the composite of Cardiovascular Death, Non-fatal Myocardial Infarction, Coronary Revascularization or Non-fatal Stroke. The number of patients with events is reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular Death</title>
        <description>Time to first occurence of Cardiovascular death. The number of patients with events was reported.</description>
        <time_frame>Up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>ticagrelor 90mg bid
ticagrelor: ticagrelor 90 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Patients in the aspirin arm will receive aspirin 81 mg daily orally
aspirin: aspirin 81 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Death</title>
          <description>Time to first occurence of Cardiovascular death. The number of patients with events was reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-fatal Myocardial Infarction or Coronary Revascularization</title>
        <description>Time to first occurence of Non-fatal myocardial infarction or coronary revascularization. The number of participants with events was reported.</description>
        <time_frame>up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>ticagrelor 90mg bid
ticagrelor: ticagrelor 90 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Patients in the aspirin arm will receive aspirin 81 mg daily orally
aspirin: aspirin 81 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Non-fatal Myocardial Infarction or Coronary Revascularization</title>
          <description>Time to first occurence of Non-fatal myocardial infarction or coronary revascularization. The number of participants with events was reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Death</title>
        <description>Time to first occurence of All-cause death. The number of participants with events was reported.</description>
        <time_frame>up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>ticagrelor 90mg bid
ticagrelor: ticagrelor 90 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Patients in the aspirin arm will receive aspirin 81 mg daily orally
aspirin: aspirin 81 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Death</title>
          <description>Time to first occurence of All-cause death. The number of participants with events was reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-fatal Stroke</title>
        <description>Time to first occurence of Non-fatal stroke. The number of participants with events was reported.</description>
        <time_frame>up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>ticagrelor 90mg bid
ticagrelor: ticagrelor 90 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Patients in the aspirin arm will receive aspirin 81 mg daily orally
aspirin: aspirin 81 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Non-fatal Stroke</title>
          <description>Time to first occurence of Non-fatal stroke. The number of participants with events was reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Number of Participants With Bleeding According to Bleeding Academic Research Consortium (BARC) Definitions</title>
        <time_frame>up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>ticagrelor 90mg bid
ticagrelor: ticagrelor 90 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Patients in the aspirin arm will receive aspirin 81 mg daily orally
aspirin: aspirin 81 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Bleeding According to Bleeding Academic Research Consortium (BARC) Definitions</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were monitored up to 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ticagrelor</title>
          <description>ticagrelor 90mg bid
ticagrelor: ticagrelor 90 mg bid</description>
        </group>
        <group group_id="E2">
          <title>Aspirin</title>
          <description>Patients in the aspirin arm will receive aspirin 81 mg daily orally
aspirin: aspirin 81 mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Venu Menon</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-445-5390</phone>
      <email>menonv@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

